Recent Finacing
Recent Raise
RS BioTherapeutics researches, develops, and commercializes endocannabinoid-system-based pulmonary inflammation therapeutics, advancing RSBT-001—a nebulized semi‑synthetic cannabidiolic acid complex—for COPD, COVID-19, cystic fibrosis, asthma, bronchitis, and ARDS.